IMA
ImageneBioCNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-18
Current thesis
IMG-007 has shown tolerability across more than 150 exposed subjects, management says ADAPTIVE is enrolling to plan, and the company now has additional financing support, so a clean 2027 readout could re-rate a stock still trading at a depressed small-cap biotech valuation [#10-K-2026-03-10].
Posture
Mixed
Lead driver
Value
What changed
Next scheduled catalyst: earnings 2026-07-22 · AMC.
What can break
Broad rather than near-dated catalyst calendar, with core topline only guided for 2027.
Momentum
58
Value
57
Sentiment
43
Setup hits (3d)
— · Net —
AI TargetsBase $5.00 · Bull $8.50 · Bear $2.80
Earnings
2026-07-22 · AMC
Data freshness
Prices
As of 2026-07-18
Fundamentals
As of 2026-07-17 • Vendor: Data Vendor v1
Scores
As of 2026-07-18 • Model: HYBRID_IC_RP
AI Memo
As of 2026-04-18 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-07-18
Investment thesis
As of 2026-07-18
Supporting evidence
What
Grade C · Mixed
Confidence Medium · Net —
Target $13.00
Why
Momentum58 · Δ7d -
Value57 · Δ7d -0.3
Sentiment43 · Δ7d -
So what
Balanced signals. Wait for confirmation before sizing up.
Lead driver: Value · See fundamentals
Momentum
58
26% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Value
57
39% active weight
Current posture
7d trendFlat
Δ7d
-0.3
Δ21d
-0.2
Sentiment
43
34% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Why this grade
Composite grade C. Momentum 58.4 / Value 57.4 / Sentiment 43.0
Fundamentals (TTM)As of 2026-07-17
Fundamentals (TTM)
As of 2026-07-17
Market Cap
$63.54M
Beta
0.44
Shares Out
11.81M
P/E (TTM) · Derived
-0.6
P/S (TTM)
-
P/FCF (TTM) · Derived
-0.91
Rev YoY
-100.0%
EPS YoY
-85.4%
Gross Margin
+9.0%
Op Margin
-10373.9%
Net Debt
-$125.35M
Current Ratio
18.39
As of 2026-07-18 • Updated nightlySource: Internal modelMethodology